Bio-Rad Launches New Kits for Meat Speciation


HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of ID-Check Speciation Solution, providing a real-time PCR method for meat speciation, or the identification of the animal species from which the meat has originated, in food, feed and environmental samples.

The identification of meat species present in food and ingredient samples is essential to verify the origin and traceability of raw materials, as well as the verification of cleaning processes in production lines. ID-Check Speciation kits are a premium quality PCR solution to provide general laboratory and research personnel with an easy and ready-to-use kit for the detection of DNA from select meat species. The kits target mitochondrial DNA in food, feed and environmental samples such as bovine, chicken, duck, goat, horse, sheep, swine and turkey species.

Under optimal conditions, these kits provide remarkable sensitivity, granting the detection in less than 2 hours with limits of detection of 0.001% (0.01% for chicken and swine). The kits were designed to allow simultaneous amplification (in multiplex) of the target meat species and an internal amplification control (IAC) to exclude false negatives due to PCR inhibition. The duplex detection system helps maximize the amplification accuracy and simplify the reaction set-up.

For more information on Bio-Rad’s ID-Check Speciation Solution, please visit:

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad 
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 8,300 employees worldwide and $2.8 billion in revenues in 2022. For more information, please visit

Forward-Looking Statements 
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contacts:
Bio-Rad Laboratories, Inc.
Wendy Lauer

CG Life
Isabella Rodriguez